03 Nov CellProthera selected for JETRO’s Japan Entry Acceleration Program
The program will support CellProthera’s market-entry strategy in Japan and help identify clinical, research and industry partnerships Mulhouse,...
Author: equipe
11 Aug CellProthera and Alfresa Holdings sign a Memorandum of Understanding to Advance Phase 3 Development and Future wholesale distribution of ProtheraCytes® in Japan
The agreement aims to accelerate the development of regenerative cell therapy for severe myocardial infarction patients in Japan.
02 Jul Technology Networks: Could Regenerative Medicine Reverse Damage After a Heart Attack?
A cell therapy approach improved patients' quality of life after a heartattack; plans for Phase 3 trials are underway.
02 Jun CellProthera Prepares For Phase 3 Push As Regenerative Cardiology Moves Closer To Clinical Reality
Matthieu de Kalbermatten, CEO of CellProthera, discusses how new board appointments, manufacturing automation, and global clinical expertise are shaping the company's strategy to advance ProtheraCytes® toward late stage development and future commercialisation.
06 May CellProthera Appoints Jérôme Hirtzlin and Anne de la Fortelle to Board of Directors for Late-Stage Clinical Development
Mulhouse, France, May 5, 2026 – CellProthera, a clinical-stage biotechnology company developing regenerative cell therapies for ischemic...
05 May Transendocardial Cell Delivery In Post‑Acute Myocardial Infarction
Myocardial infarction (MI) remains a leading cause of heart failure worldwide despite major advances in reperfusion and pharmacologic therapy.
28 Apr CellProthera Collaborates with Quintessence Biotech to Industrialize Cell Manufacturing Processes Ahead of Stroke Clinical Trials
CellProthera will use Quintessence’s DACSTM flotation‑based cell sorting platform for its potential to enhance therapeutic purity and...
16 Apr Why A Cell Therapy CEO Waited Until Phase III To Outsource
Sometimes, you have to go it alone. For a while, at least.
15 Apr Manufacturing Cell and Gene Therapies: Getting Advanced Therapies into Patients
Biopharmaceutical companies, regulators, and other stakeholders are aligned on the need to accelerate cell and gene therapy (CGT) development...
19 Mar CellProthera sets the scene for Phase III stem cell therapy trial
The biotech will soon evaluate the safety and efficacy of its regenerative cardiovascular stem cells, coined ProtheraCytes, in a Phase III trial.